ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: KEY EFFICACY AND SAFETY RESULTS FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2

被引：0

作者：

Simpson, Eric L. ^{[1
]}

Silverberg, Jonathan I. ^{[2
]}

Forman, Seth ^{[3
]}

Wollenberg, Andreas ^{[4
]}

Thyssen, Jacob P. ^{[5
]}

Flohr, Carsten ^{[6
]}

Feeney, Claire ^{[7
]}

Biswas, Pinaki ^{[8
]}

DiBonaventura, Marco ^{[9
]}

Cameron, Michael C. ^{[10
]}

Rojo, Ricardo ^{[11
]}

Valdez, Hernan ^{[12
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA

[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA

[3] ForCare Clin Res, Dept Dermatol, Tampa, FL USA

[4] Ludwig Maximilian Univ Munich, Dept Dermatol, Munich, Germany

[5] Univ Copenhagen, Dept Dermatol & Allergy, Herlev & Gentofte Hosp, Hellerup, Denmark

[6] St Johns Inst Dermatol, Unit Populat Based Dermatol Res, London, England

[7] Pfizer Ltd, Global Med Affairs Inflammat & Immunol, Tadworth, Surrey, England

[8] Pfizer Inc, Biostat, New York, NY USA

[9] Pfizer Inc, Patient & Hlth Impact Inflammat & Immunol, New York, NY USA

[10] Pfizer Inc, North Amer Med Affairs Inflammat & Immunol, New York, NY USA

[11] Pfizer Inc, Global Prod Dev Inflammat & Immunol, Groton, CT 06340 USA

[12] Pfizer Inc, Global Prod Dev Inflammat & Immunol, New York, NY USA

来源：

ACTA DERMATO-VENEREOLOGICA | 2021年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

OL10

引用

页码：13 / 14

页数：2

共 50 条

[31] Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2
Gil Yosipovitch
Melinda J. Gooderham
Sonja Ständer
Luz Fonacier
Jacek C. Szepietowski
Mette Deleuran
Giampiero Girolomoni
John C. Su
Andrew G. Bushmakin
Joseph C. Cappelleri
Claire Feeney
Gary Chan
Andrew J. Thorpe
Hernan Valdez
Pinaki Biswas
Ricardo Rojo
Marco DiBonaventura
Daniela E. Myers
American Journal of Clinical Dermatology, 2024, 25 : 127 - 138
[32] Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
Li, Ling
Yu, Jiajun
Chen, Baoqing
Guo, Ying
Yang, Yufeng
FRONTIERS IN PHARMACOLOGY, 2023, 14
[33] Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
Gooderham, Melinda J.
Weidinger, Stephan
Simpson, Eric L.
Deleuran, Mette
Gold, Linda F. Stein
Farooqui, Saleem A.
Biswas, Pinaki
Chan, Gary
Guler, Erman
Koppensteiner, Herwig
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II32 - II33
[34] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
Alexis, Andrew
de Bruin-Weller, Marjolein
Weidinger, Stephan
Soong, Weily
Barbarot, Sebastien
Ionita, Ileana
Zhang, Fan
Valdez, Hernan
Clibborn, Claire
Yin, Natalie
DERMATOLOGY AND THERAPY, 2022, 12 (03) : 771 - 785
[35] Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study
McMichael, Amy
Cork, Michael
Teng, Joyce
Rojo, Ricardo
Valdez, Hernan
Zhang, Fan
Myers, Daniela
Chan, Gary
DiBonaventura, Marco
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB156 - AB156
[36] Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
Andrew Alexis
Marjolein de Bruin-Weller
Stephan Weidinger
Weily Soong
Sebastien Barbarot
Ileana Ionita
Fan Zhang
Hernan Valdez
Claire Clibborn
Natalie Yin
Dermatology and Therapy, 2022, 12 : 771 - 785
[37] Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE
Silverberg, Jonathan I.
Simpson, Eric L.
Pink, Andrew E.
Weidinger, Stephan
Chan, Gary
Biswas, Pinaki
Clibborn, Claire
Guler, Erman
DERMATOLOGY AND THERAPY, 2025, 15 (02) : 367 - 380
[38] Impact of self-reported comorbid food allergy on efficacy and safety of abrocitinib and dupilumab in patients with moderate-to-severe atopic dermatitis: A pooled analysis of JADE COMPARE and JADE DARE
Geng, B.
Nosbaum, A.
Boguniewicz, M.
Vestergaard, C.
Lazariciu, I.
Feeney, C.
Rebollo, F. J.
Koppensteiner, H.
Hernandez-Martin, I.
ALLERGY, 2023, 78 : 140 - 140
[39] Efficacy of abrocitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis who had an inadequate response or intolerance to nonsteroidal immunosuppressants: results from JADE DARE
Ardern-Jones, Michael
Ameen, Mahreen
de Bruin-Weller, Marjolein
Simpson, Eric
Chiu, Wing Sin
Zhang, Fan
Chan, Gary
Koulias, Christopher
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 71 - 72
[40] Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long Term Extension Study
Shi, Vivian Y.
Bhutani, Tina
Deleuran, Mette
Fonacier, Luz
Shumack, Stephen
Zhang, Fan
Cameron, Michael C.
Chan, Gary
Valdez, Hernan
Yin, Natalie
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 78

← 1 2 3 4 5 →